TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

Rachel A. Freedman(Dana-Farber Cancer Institute), Nancy U. Lin(Dana-Farber Cancer Institute), Julie R. Nangia(Unknown), Carey K. Anders(Duke University), Beverly Moy(Global Cancer Institute), Rachel C. Jankowitz(University of Pennsylvania), Paula R. Pohlmann(The University of Texas MD Anderson Cancer Center), Antonio C. Wolff(Johns Hopkins University), Juan M. Marte(Dana-Farber Cancer Institute), Ian E. Krop(Yale Cancer Center), Catherine Van Poznak(University of Michigan), Polly Niravath(Houston Methodist), Nadine Tung(Beth Israel Deaconess Medical Center), Kelly M. Silvestri(Dana-Farber Cancer Institute), Robyn Burns(Breast Cancer Research Foundation), Ciara C. O’Sullivan(Mayo Clinic in Arizona), Timothy J. Moynihan(Mayo Clinic), Rebecca Gelman(Dana-Farber Cancer Institute), Eric P. Winer(University of Vermont), Kathryn P. Componeschi(Dana-Farber Cancer Institute), Mothaffar F. Rimawi(Baylor College of Medicine), Karen L. Smith(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nuhad K. Ibrahim(The University of Texas MD Anderson Cancer Center), Christine M. Cotter(Dana-Farber Cancer Institute), Heather A. Parsons(Harvard University), Shannon L. Puhalla(NSABP Foundation), Anne B. Cropp(Pfizer (United States)), Michelle Melisko(University of California, San Francisco), Kimberly Blackwell(Duke University), Roisín M. Connolly(Johns Hopkins University)
Journal of Clinical Oncology
March 12, 2019
Cited by 341


Related Papers